tbuckley/cabot-search huggingface dataset:
CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan
Authors: Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung, Taewoong Choi
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion
Authors: Jeong Uk Choi, Ruby Maharjan, Rudra Pangeni, Saurav Kumar Jha, Na Kyeong Lee, Seho Kweon, Ha Kyeong Lee, Kwan-Young Chang, Young Kweon Choi, Jin Woo Park, Youngro Byun
Journal: Journal of Controlled Release (2020)
Efficacy and safety profile of oxaliplatin and docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
Authors: E. S. Santos, L. E. Raez, M. Rosado, G. Lopes, E. Roman, P. Kumar, K. Tolba, O. Silva, C. Rocha-Lima, K. Hamilton
Journal: Journal of Clinical Oncology (2006)

17061 Background: Platinum-based doublets are used as treatment for advanced or metastatic non-small cell lung cancer (NSCLC), but chemotherapy must be tailored to decrease side effects. Oxaliplatin is more potent than cisplatin, requiring fewer DNA adducts to provide equivalent cytotoxicity in vitro studies. Oxaliplatin was active as a single agent and in combination with vinorelbine, paclitaxel, and gemcitabinein phase II studies of patients with NSCLC. A phase II study was conducted to evaluate the efficacy and safety of oxaliplatin combined with docetaxel for NSCLC. Methods: Patients with stage-IIIB or -IV, chemotherapy-naive NSCLC received docetaxel 70 mg/m 2 , oxaliplatin 130 mg/m 2 , and pegfilgrastim 6 mg every 21 days for up to 6 cycles. The primary endpoint was overall response rate (ORR); secondary endpoints were progression-free and overall survival (PFS and OS), and safety. Results: Twenty-nine patients were treated; 15 (51.7%) were women, 25 (76%) were white, 17 (58.6%) were hispanic, 21 (72.4%) had adenocarcinomas, 24 (83%) had a PS ECOG 1, 93% had stage-IV disease and 28% had brain metastases. There were 10 partial responses in 27 evaluable patients for an ORR of 37% (90% confidence interval [CI], 21.7%–54.7%). Median PFS for 29 treated patients was 4.6 months (95% CI, 2.6–6.5 months); 12-month PFS was 14.8% (95% CI, 3.4%– 34.0%). Median OS was 10.9 months (95% CI, 8.9–16.8 months); 12-month OS was 40% (95% CI, 18.5%–60.8%) and 18-month OS was 16% (95% CI, 1.4%–45.7%). There were no unusual or unexpected adverse events. The most common grade-3 and -4 toxicities were anemia (14% of patients) and hyperglycemia (10%). There were only 2 reports of neutropenia; both were grade 1 or 2. Conclusions: These phase II findings suggest that the combination of oxaliplatin and docetaxel is active and well tolerated, and offers a feasible treatment alternative for patients with advanced or metastatic NSCLC. [Table: see text]
IMPACT OF THE REVERSAL OF ELEVATED PULMONARY VASCULAR RESISTANCE WITH LEFT VENTRICULAR ASSIST DEVICE OR CHRONIC VASODILATORS ON POST HEART TRANSPLANT CLINICAL OUTCOMES
Authors: Sneha Jain, Zachary Roth, Kevin Clerkin, Justin Fried, Jayant Raikhelkar, Paolo Colombo, MaryJane A. Farr, Veli Topkara, Melana Yuzefpolskaya, Yoshifumi Naka, Koji Takeda, Nir Uriel, Gabriel Sayer
Journal: Journal of the American College of Cardiology (2020)
Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis
Authors: Lisen Lu, Shuhong Qi, Yuzhou Chen, Haiming Luo, Songlin Huang, Xiang Yu, Qingming Luo, Zhihong Zhang
Journal: Biomaterials (2020)
Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study
Authors: En Cheng, Peiyin Hung, Shi-Yi Wang
Journal: Journal of the National Comprehensive Cancer Network (2020)

Background: Transplantation, surgical resection, radiofrequency ablation, and percutaneous ethanol injection are generally considered potentially curative treatments for patients with hepatocellular carcinoma (HCC). With the increasing incidence of HCC, it is critical to investigate geographic variations in curative treatments and their associations with survival among patients. Methods: A total of 6,782 patients with HCC during 2004 to 2011 were identified in the SEER-Medicare linked database and placed in quartiles based on the proportions undergoing potentially curative treatments per hospital referral region (HRR). Hierarchical Cox proportional hazards models were used to examine the association between regional potentially curative treatment patterns and survival across quartiles. Results: An average of 16.9% of patients with HCC underwent potentially curative treatments during 2004 to 2011, varying substantially from 0% to 34.5% across HRRs. Compared with patients residing in the lowest-quartile regions, those in the highest-quartile regions were more likely to be of other races (vs white or black), be infected with hepatitis B virus, and have more comorbidities. The 5-year survival was 4.7% in the lowest-quartile regions and 11.4% in the highest-quartile regions ( P &lt;.001). After controlling for confounders, patients in the highest-quartile regions had a lower risk of mortality (adjusted hazard ratio, 0.78; 95% CI, 0.72–0.85). Conclusions: Patients with HCC who resided in HRRs with higher proportions of potentially curative treatments had better survival. Given its proven survival benefits, prompt clinical and policy actions are needed to reduce variations in treatment utilization.
STATIN TREATMENT AND RISK OF CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH MYOCARDIAL INFARCTION IN AN INTEGRATED HEALTHCARE SYSTEM
Authors: Yangyang Liu, Rasha Alkhatib, Yi Li, Abdelhadi Rifai, Pallavi Rane, Mohdhar Habib, Belinda Schludi, Rolin Wade, Catherine McGuiness, Neal Sawlani
Journal: Journal of the American College of Cardiology (2020)
EXOSOME-DERIVED CIRCITGB1 REGULATES DENDRITIC CELL MATURATION AND CARDIAC INFLAMMATION VIA MIR-342-3P/NFAM1
Authors: Jianbing Zhu, Zhaoyang Chen, Qian Wang, Xiaoping Peng, Zhenzhong Zheng, Aiping Le, Zeqi Zheng, Junbo Ge
Journal: Journal of the American College of Cardiology (2020)
Intestinal Microbiome‐Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice
Authors: Anna Isaacs‐Ten, Marta Echeandia, Mar Moreno‐Gonzalez, Arlaine Brion, Andrew Goldson, Mark Philo, Angela M. Patterson, Aimee Parker, Mikel Galduroz, David Baker, Simon M. Rushbrook, Falk Hildebrand, Naiara Beraza
Journal: Hepatology (2020)

Background and Aims Mounting evidence supports an association between cholestatic liver disease and changes in the composition of the microbiome. Still, the role of the microbiome in the pathogenesis of this condition remains largely undefined. Approach and Results To address this, we have used two experimental models, administering alpha‐naphtylisocyanate or feeding a 0.1% 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine diet, to induce cholestatic liver disease in germ‐free mice and germ‐free mice conventionalized with the microbiome from wild‐type, specific pathogen‐free animals. Next, we have inhibited macrophage activation by depleting these cells using clodronate liposomes and inhibiting the inflammasome with a specific inhibitor of NOD‐, LRR‐, and pyrin domain‐containing protein 3. Our results demonstrate that cholestasis, the accumulation of bile acids in the liver, fails to promote liver injury in the absence of the microbiome in vivo . Additional in vitro studies supported that endotoxin sensitizes hepatocytes to bile‐acid–induced cell death. We also demonstrate that during cholestasis, macrophages contribute to promoting intestinal permeability and to altered microbiome composition through activation of the inflammasome, overall leading to increased endotoxin flux into the cholestatic liver. Conclusions We demonstrate that the intestinal microbiome contributes to cholestasis‐mediated cell death and inflammation through mechanisms involving activation of the inflammasome in macrophages.
Risk of mineralocorticoid excess syndrome with CYP17 inhibitor abiraterone in prostate cancer patients.
Authors: Sandy Ann Itwaru, Arun Gopal, Omer Bashir, Joomee Shim, Xiaolei Zhu, Shenhong Wu
Journal: Journal of Clinical Oncology (2012)

e15140 Background: CYP17 inhibitor abiraterone acetate has been used for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC). Hypertension, hypokalemia and edema are the major side effects associated with its use, and may be secondary to the excess of mineralocorticoids due to CYP17 inhibition. We performed a systematic review and meta-analysis of published clinical trials to determine the effect of abiraterone on the development of these side effects. Methods: Databases including Pubmed (July, 1966 to July, 2011), Web of Science, and abstracts presented at the American Society of Clinical Oncology meetings from 2008 to 2011 were searched to identify relevant studies. Eligible studies were prospective clinical trials of patients with prostate cancer receiving abiraterone acetate at the starting dose of 1,000 mg daily with available data on hypertension, hypokalemia and edema. Incidence and relative risk (RR) were calculated using a random-effects or fixed-effects model. Results: A total of seven studies including 1,387 patients with CRPC were selected for analysis. The incidences of all-grade hypertension, hypokalemia, and edema were 13.3% (95% CI: 8.3 to 20.5%), 31.4 % (95% CI: 12.5-59.5%), and 23.4 % (95% CI: 15.6-33.5%) respectively. The incidences of high-grade (grade 3 and above) toxicity were low, with a rate of 3.6% (95% CI: 2.6-5.1%), 2.8 % (95% CI: 0.9 to 8.2%), and 2.1% (95%CI: 1.3-3.2%) for hypertension, hypokalemia, and edema respectively. The risk of hypertension and edema did not change with and without the addition of prednisone (p=0.48 and p=0.40, respectively); however, the risk of hypokalemia was significantly reduced with the addition of prednisone (p = 0.003). In comparison with prednisone alone, the addition of abiraterone did not increase the risk of hypertension (RR 1.22, 95% CI: 0.82 – 1.83, p=0.31), but significantly increased the risk of edema (RR 1.36, 95% CI: 1.10-1.69, p=0.004) and hypokalemia (RR 2.04, 95% CI: 1.42–2.92, p&lt;0.001). Conclusions: There were differential effects of abiraterone on the development of hypertension, hypokalemia, and edema in patients with advanced prostate cancer. Further studies are recommended for optimal treatment.
MANAGEMENT AND OUTCOMES OF CARDIOGENIC SHOCK IN CARDIAC ICUS WITH AND WITHOUT SHOCK TEAMS: DATA FROM THE CRITICAL CARE CARDIOLOGY TRIALS NETWORK (CCCTN) REGISTRY
Authors: Alexander Papolos, Christopher Barnett, Ben Kenigsberg, Anson Brown, Erin Ann Bohula, David Berg, Jianping Guo, Sean Van Diepen, Jason Katz, David A. Morrow
Journal: Journal of the American College of Cardiology (2020)
mtDNA Activates cGAS Signaling and Suppresses the YAP-Mediated Endothelial Cell Proliferation Program to Promote Inflammatory Injury
Authors: Long Shuang Huang, Zhigang Hong, Wei Wu, Shiqin Xiong, Ming Zhong, Xiaopei Gao, Jalees Rehman, Asrar B. Malik
Journal: Immunity (2020)
Hypersensitivities following allergen antigen recognition by unconventional T cells
Authors: Marcela de Lima Moreira, Michael N. T. Souter, Zhenjun Chen, Liyen Loh, James McCluskey, Daniel G. Pellicci, Sidonia B. G. Eckle
Journal: Allergy (2020)

Conventional T cells recognise protein-derived antigens in the context of major histocompatibility complex (MHC) class Ia and class II molecules and provide anti-microbial and anti-tumour immunity. Conventional T cells have also been implicated in type IV (also termed delayed-type or T cell-mediated) hypersensitivity reactions in response to protein-derived allergen antigens. In addition to conventional T cells, subsets of unconventional T cells exist, which recognise non-protein antigens in the context of monomorphic MHC class I-like molecules. These include T cells that are restricted to the cluster of differentiation 1 (CD1) family members, known as CD1-restricted T cells, and mucosal-associated invariant T cells (MAIT cells) that are restricted to the MHC-related protein 1 (MR1). Compared with conventional T cells, much less is known about the immune functions of unconventional T cells and their role in hypersensitivities. Here, we review allergen antigen presentation by MHC-I-like molecules, their recognition by unconventional T cells, and the potential role of unconventional T cells in hypersensitivities. We also speculate on possible scenarios of allergen antigen presentation by MHC-I-like molecules to unconventional T cells, the hallmarks of such responses, and the expected frequencies of hypersensitivities within the human population.
Automatic, wearable-based, in-field eating detection approaches for public health research: a scoping review
Authors: Brooke M. Bell, Ridwan Alam, Nabil Alshurafa, Edison Thomaz, Abu S. Mondol, Kayla de la Haye, John A. Stankovic, John Lach, Donna Spruijt-Metz
Journal: npj Digital Medicine (2020)

Abstract Dietary intake, eating behaviors, and context are important in chronic disease development, yet our ability to accurately assess these in research settings can be limited by biased traditional self-reporting tools. Objective measurement tools, specifically, wearable sensors, present the opportunity to minimize the major limitations of self-reported eating measures by generating supplementary sensor data that can improve the validity of self-report data in naturalistic settings. This scoping review summarizes the current use of wearable devices/sensors that automatically detect eating-related activity in naturalistic research settings. Five databases were searched in December 2019, and 618 records were retrieved from the literature search. This scoping review included N = 40 studies (from 33 articles) that reported on one or more wearable sensors used to automatically detect eating activity in the field. The majority of studies ( N = 26, 65%) used multi-sensor systems (incorporating &gt; 1 wearable sensors), and accelerometers were the most commonly utilized sensor ( N = 25, 62.5%). All studies ( N = 40, 100.0%) used either self-report or objective ground-truth methods to validate the inferred eating activity detected by the sensor(s). The most frequently reported evaluation metrics were Accuracy ( N = 12) and F1-score ( N = 10). This scoping review highlights the current state of wearable sensors’ ability to improve upon traditional eating assessment methods by passively detecting eating activity in naturalistic settings, over long periods of time, and with minimal user interaction. A key challenge in this field, wide variation in eating outcome measures and evaluation metrics, demonstrates the need for the development of a standardized form of comparability among sensors/multi-sensor systems and multidisciplinary collaboration.
PCI PROVIDES COSTLY MORTALITY REDUCTIONS FOR BREAST CANCER PATIENTS: PROPENSITY SCORE AND MACHINE LEARNING AUGMENTED NATIONALLY REPRESENTATIVE CASE-CONTROL STUDY OF 30 MILLION+ HOSPITALIZATIONS
Authors: Dominique Monlezun, Rahul Gaiba, Konstantinos Marmagkiolis, Mehmet Cilingiroglu, Juan C. Lopez-Mattei, Peter Y. Kim, Siddharth Chauhan, Kenneth Hoang, Messan Folvi, Logan Hostetter, Sophia Lee, Ananya Yalamanchi, Monica Tamil, Jeffrey Chen, Tariq Thannoun, Cullen Grable, Natalie Chen, Nicole Thomason, Vivian Okirie, Nicolas Palaskas, Jessica Colen, Sarah DeSnyder, Cezar Iliescu
Journal: Journal of the American College of Cardiology (2020)
IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease
Authors: Kathleen M. Buchheit, Daniel F. Dwyer, Jose Ordovas-Montanes, Howard R. Katz, Erin Lewis, Marko Vukovic, Juying Lai, Lora G. Bankova, Neil Bhattacharyya, Alex K. Shalek, Nora A. Barrett, Joshua A. Boyce, Tanya M. Laidlaw
Journal: Journal of Allergy and Clinical Immunology (2020)
ABNORMAL SERUM CHLORIDE IS ASSOCIATED WITH INCREASED MORTALITY AMONG UNSELECTED CARDIAC INTENSIVE CARE UNIT PATIENTS
Authors: Thomas Breen, Mitchell Padkins, Benjamin Brueske, Mandeep S. Sidhu, Kianoush Kashani, Nandan Sadanand Anavekar, Gregory W. Barsness, Jacob Colin Jentzer
Journal: Journal of the American College of Cardiology (2020)
Abstract 13833: Impact of Lowering LDL-C With Evolocumab on Everyday Cognition in Participants From the FOURIER Trial
Authors: Baris Gencer, François Mach, Jianping Guo, Kyungah Im, Andrea Ruzza, Huei Wang, Christopher Kurtz, Terje R Pedersen, Anthony C Keech, Brian Ott, Marc S Sabatine, Robert P Giugliano
Journal: Circulation (2019)

Background: The EBBINGHAUS trial demonstrated that LDL-C lowering with the addition of evolocumab to background statin did not affect cognitive function in 1,204 patients from the FOURIER trial who...
Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases
Authors: Nienke Z. Borren, Damian Plichta, Amit D. Joshi, Gracia Bonilla, Vincent Peng, Francis P. Colizzo, Jay Luther, Hamed Khalili, John J. Garber, C. Janneke van der Woude, Ruslan Sadreyev, Hera Vlamakis, Ramnik J. Xavier, Ashwin N. Ananthakrishnan
Journal: Clinical Gastroenterology and Hepatology (2020)
CLINICOPATHOLOGICAL IMPLICATIONS OF PRKAR1A MUTATION IN PATIENTS WITH CARDIAC MYXOMA: POOLED DATA ANALYSIS FROM 101 MYXOMA CASES
Authors: Ahmed Altibi, Lama Al Jebbawi, Brijesh D. Patel, Huy Gia Vuong, Ahmad Munir Masri
Journal: Journal of the American College of Cardiology (2020)
Immunotherapy of multiple myeloma
Authors: Simone A. Minnie, Geoffrey R. Hill
Journal: Journal of Clinical Investigation (2020)

Multiple myeloma (MM), a bone marrow-resident hematological malignancy of plasma cells, has remained largely incurable despite dramatic improvements in patient outcomes in the era of myeloma-targeted and immunomodulatory agents. It has recently become clear that T cells from MM patients are able to recognize and eliminate myeloma, although this is subverted in the majority of patients who eventually succumb to progressive disease. T cell exhaustion and a suppressive bone marrow microenvironment have been implicated in disease progression, and once these are established, immunotherapy appears largely ineffective. Autologous stem cell transplantation (ASCT) is a standard of care in eligible patients and results in immune effects beyond cytoreduction, including lymphodepletion, T cell priming via immunogenic cell death, and inflammation; all occur within the context of a disrupted bone marrow microenvironment. Recent studies suggest that ASCT reestablishes immune equilibrium and thus represents a logical platform in which to intervene to prevent immune escape. New immunotherapies based on checkpoint inhibition targeting the immune receptor TIGIT and the deletion of suppressive myeloid populations appear attractive, particularly after ASCT. Finally, the immunologically favorable environment created after ASCT may also represent an opportunity for approaches utilizing bispecific antibodies or chimeric antigen receptor T cells.
Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience.
Authors: Yuka Kato, Eiki Ichihara, Katsuyuki Hotta, Akiko Hisamoto, Nagio Takigawa, Naoyuki Nogami, Toshiyuki Kozuki, Kenichiro Kudo, Masahiro Tabata, Tetsu Shinkai, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Journal of Clinical Oncology (2012)

7576 Background: EGFR-TKI (E) therapy yielded a better PFS than standard cytotoxic chemotherapy (C) therapy and a comparable OS in untreated pts with EGFR-mt tumors, suggesting each of the treatments is now crucial for such subpopulation. But, it has not been fully evaluated yet which of each should be initiated first, and to what degree both of two are actually administered in early line setting in the treatment course. We here investigated a potential difference in incidence and pattern of delivery of subsequent crossover therapy after failure to each of the treatments in pts with EGFR-mt tumors. Methods: Consecutive 79 pts with advanced EGFR-mt NSCLC were retrospectively assessed who underwent E therapy (n = 39) or standard C therapy (n = 40) in the 1st-line setting between 2007 and 2011. Results: In E group 16 (41%) of 39 pts were still on 1st-line E therapy. Nine (39%) of the remaining 23 could not receive standard C therapy after failure to E therapy due to symptomatic CNS metastasis(mets) in 6, skeletal events in 2, and patient refusal in 1, whilst in C group only one (3%) of 40 failed to receive subsequent E therapy because of relapse (carcinomatous lymphangitis) (χ 2 -test; p &lt; .001). Also, at the time of relapse to the 1-st line therapy, PS deteriorated more frequently in E group (8/23 vs. 7/40; p = .042) and, relapse with symptomatic CNS mets seemed frequently observed in E group (6/23 vs. 4/40; p = .093). Multivariate analysis revealed type of regimens undergone in the 1st-line setting (E vs. C) correlated with failure of administration of subsequent crossover therapy (odd ratio: 3.224, 95%CI: .1.032 – 5,417, p = .004). Conclusions: It seems that pts with EGFR-mt tumors who were treated with 1st-line C had better opportunity to receive post-progression E therapy than those treated with 1st-line E had chance to receive subsequent C therapy, possibly due to difference in PS deterioration rate and relapse pattern.
Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy
Authors: P.-A. Bolze, B. You, J.-P. Lotz, J. Massardier, L. Gladieff, F. Joly, T. Hajri, D. Maucort-Boulch, S. Bin, A. Roux, P. Rousset, L. Villeneuve, M. Alves-Ferreira, D. Grazziotin-Soares, C. Mercier, G. Freyer, F. Golfier
Journal: Annals of Oncology (2020)